Individualized therapy in statin intolerance: the key to success
Eur Heart J
.
2023 Feb 14;44(7):544-546.
doi: 10.1093/eurheartj/ehac556.
Authors
Maciej Banach
1
2
3
,
Christopher P Cannon
4
,
Francesco Paneni
5
6
,
Peter E Penson
7
8
;
endorsed by the International Lipid Expert Panel (ILEP)
Affiliations
1
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Rzgowska 281/289, 93-338 Lodz, Poland.
2
Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
3
Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
4
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
5
University Heart Center, Department of Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland.
6
Center for Translational and Experimental Cardiology (CTEC), University Hospital Zurich and University of Zurich, Switzerland.
7
Clinical Pharmacy & Therapeutics Research Group, School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
8
Liverpool Centre for Cardiovascular Science, Liverpool, UK.
PMID:
36254670
DOI:
10.1093/eurheartj/ehac556
No abstract available
MeSH terms
Cardiovascular Diseases*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Risk Factors
Substances
Hydroxymethylglutaryl-CoA Reductase Inhibitors